Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec in Localized Prostate Cancer
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
BTV Spotlights: NevGold, Calian Group, Talisker Resources, Dakota Gold, Oreterra Metals, Titan Mining, Nevada Organic Phosphate, Osisko Development
BTV Spotlights: NevGold, Calian Group, Talisker Resources, Dakota Gold, Oreterra Metals, Titan Mining, Nevada Organic Phosphate, Osisko Development
SAGA Metals Completes Acquisition of Wolverine Heavy Rare Earth Element Project in Labrador-REE Mineralized Potential Similar to Strange Lake and Tanbreez
